Navigation Links
PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
Date:11/9/2009

EXEL International. "Our alliance with Mortara Instrument provides customers with improved automation in the acquisition and reporting of ECG data for greater data accuracy and faster, better decision making. This relationship represents our commitment to providing comprehensive early phase cardiovascular expertise and capabilities, such as intensive ECG and thorough QT/QTc studies, supported by enabling technologies."

Each of PAREXEL's early phase clinical units has state-of-the-art equipment and performs cardiac studies according to international guidelines. The units are equipped with telemetric and bedside monitoring as well as ECG equipment for continuous registration. PAREXEL's early phase experts provide top-quality, evidence-supported readings of clinical cardiovascular data and work in collaboration with ECG core labs. PAREXEL's early phase services include a wide range of cardiovascular-related capabilities, including study design, project monitoring, data management, and biostatistics.

PAREXEL's early phase services provide fully integrated solutions from First in Man through Proof of Concept and help biopharmaceutical companies generate better and faster go/no-go decisions about their compounds, and strive to return solid, reproducible outcomes to succeed in later-phase trials. PAREXEL's early phase capabilities include a full scope of early phase studies, specialized trial design, state-of-the-art technologies, hospital-based resources, and scientific expertise as well as vast experience in the neurology, cardiology, respiratory, and metabolism/endocrine therapeutic areas. With early phase unit locations across three continents, PAREXEL provides rapid study start-up and access to diverse patient populations in addition to healthy volunteers. For more information about PAREXEL's early phase capabilities visit: http://www.PAREXEL.com/Early_Phase.html.

Mortara, w
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
9. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
10. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
11. Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
(Date:7/28/2014)... ORLANDO, Fla. , July 28, 2014 /PRNewswire/ ... "Company"), a biopharmaceutical company focused on the development, ... that it has filed definitive proxy materials with ... its 2014 Annual Meeting of Shareholders to be ... a.m., East Standard Time. The record date for ...
Breaking Medicine Technology:Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ... clinical,trial showing that KOS-1584/R1645, an epothilone under,co-development ... in patients with solid tumors.,KOS-1584/R1645 showed activity ... including activity in patients with non-small cell ...
... Investigational cancer drug Pertuzumab shows promising results ... Phase III,development initiated, BASEL, Switzerland, June 4, ... exciting new cancer medicine pertuzumab, a HER,dimerisation ... pre-treated HER2 positive breast cancer, when,combined with ...
Cached Medicine Technology:Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 2Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 3Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 4Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO 5Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 2Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 3Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 4Investigational Cancer Drug Pertuzumab Shows Promising Results in,Advanced Breast Cancer When Combined with Herceptin 5
(Date:7/28/2014)... New York, NY (PRWEB) July 28, 2014 ... tickets for the Guinness International Champions Cup Match between ... new Yankee Stadium in the Bronx has hosted countless big ... have the charm and history of the original Yankee Stadium, ... events in the New York City metro area. , ...
(Date:7/28/2014)... Scottsdale, Ariz (PRWEB) July 28, 2014 ... closed on a new camp property in Cornville, ... provides seriously ill children with the opportunity to ... the campers and families. The organization offers a ... ages 6-15 with chronic and life threatening illnesses ...
(Date:7/28/2014)... Quincy Bioscience, makers of the nation’s leading memory ... release of the fourth edition of The Brain Health ... , The Brain Health Guide is a unique resource ... to improve memory and promote optimal aging. Rather than ... Guide provides ways to help minimize common memory lapses ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... takes humans just milliseconds to look at someone,s face and ... study finds that certain facial features seem to trigger specific ... and size of the mouth, for example, appear directly linked ... to attractiveness. The study findings suggest that first ...
(Date:7/28/2014)... Ticket Down is reliable source ... Dallas, TX at the Cotton Bowl. The 2014 Guinness ... and it is an eight team tourney. The tournament ... teams from La Liga, Serie A, English Premier League, and ... out on the pitch include: Manchester United, Manchester City, ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3
... Products from AnaSpec, Accelrys, Almac Diagnostics, Seahorse Biosciences, BioFortis recognized ... ... San Francisco, CA (PRWEB) March 3, 2009 ... biotech companies that have won the Third Annual Best ...
... American Journal of Epidemiology , Oregon Research Institute ... a high-density of fast food outlets was associated with ... inches in waist circumference among neighborhood residents who frequently ... associated with a decrease of 2.7 pounds in weight ...
... types of child maltreatment are robust risk factors for ... that explored the influence of social environment on the ... appears in the current issue of Addictive Behaviors ... more alcoholic drinks on a single occasion at least ...
... 3 TouchMark, a division of Delphon Industries and industry ... is offering complimentary NRE (Non-Recurring Engineering or set-up fees) on ... customer who submits a new Pad Print order will not ... our customers, loyalty to TouchMark," says Jeanne Beacham, CEO. ...
... BOSTON, March 3 Important deadlines are approaching ... settlement related to the average wholesale prices of ... for the District of Massachusetts granted preliminary approval ... In the lawsuit, In re: Pharmaceutical Industry ...
... 3 Rochester Medical Corporation (Nasdaq: ROCM ... the company,s outstanding common shares pursuant to its previously ... repurchase shares from time to time on the open ... accordance with applicable SEC guidelines and regulations. Additionally, the ...
Cached Medicine News:Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 2Health News:Best New Product Awards Winners Named at Molecular Medicine Tri-Conference 3Health News:Fast-food density and neighborhood walkability affect residents' weight and waist size 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 2Health News:How multiple childhood maltreatments lead to greater adolescent binge drinking 3Health News:Important Deadlines Near for $21 Million Class Action Settlement That Provides Consumers With Money Back for Over 200 Prescription Drugs 2Health News:Rochester Medical Renews Share Repurchase Activity 2
...
... FLEXILOG antimony pH catheters are designed for patient ... ,All catheters are number marked at 5cm intervals ... than sixteen individual models are available spanning most ... or multi-use models with one or two sensors., ...
... The Standard VersaFlex™ disposable pH ... nurses, and clinics worldwide for evaluating ... catheters for 24-hour esophageal pH monitoring. ... the smallest diameter esophageal catheter on ...
FLEXILOG accessory....
Medicine Products: